- Email: [email protected]
Pre-operative magnetic resonance imaging of stage 1 endometrial adenocarcinoma
Citations from the Literature carcinoma and positive para-aortic nodes in this study was 57.1%. Four patients have survived for 1, 30, 60, and 71 months. There were no surgical deaths or radiation therapy complications directly attributable to paraaortic biopsy or irradiation. Preoperative magnetic resonance imaging of stage 1 endomelxial adenocarcinoma Powell MC; Womack C; Buckely J; et al. Department of Obstetrics and Gynaecology, Hospital, Queen’s Medical Centre, Nottingham
University NG7 2VH.
UK BR. J. OBSTET. GYNAECOL.; 93/4 (353-360) 1986 Twelve women with stage I endometrial adenocarcinoma were examined by magnetic resonance imaging before definitive surgery. Using this technique the depth of myometrical invasion, tumour site and cervical involvement were assessed and the results compared with the operative and pathological findings. Magnetic resonance imaging is a unique non-invasive method of assessing the early stages of endometrial adenocarcinoma before radiotherapy and surgery.
Random urinary cyclic 3’, 5’ guanosine monophosphate in epithelial ovarian cancer: Relation to other prognostic variables and to survival Luesley DM; Blackledge GR; Chan KK; Newton JR Department Bimingham,
of Obstetrics and Gymsecology. Birmingham, UK
University of
BR. J. OBSTET. GYNAECOL.; 93/4 (380-385) 1986 Random urinary cyclic guanosine monophosphate (cyclic GMP) has been measured in a control group of 83 women and in 92 women with histologically proven epithelial ovarian cancer. Forty-eight cancer patients (53%) had levels greater than the mean +25D of the control population. There was no correlation between urinary cyclic GMP and tumour histology, degree of differentiation or stage. Patients with gross residual disease after laparotomy had higher postoperative levels, This degree of sensitivity in addition to poor specificity for ovarian cancer renders this marker unsuitable for screening purposes. While residual disease state after surgery was found to be the best single predictor of survival, an elevated urinary cyclic GMP level before chemotherapy was found to be an independent adverse prognostic variable.
Complete remission at laparotomy: Still a gold standard in ovarian cancer? Neijt JP; Ten Bokkel Huinink WW; Van Der Burg MEL; Van Oosterom AT Netherlands Joint Study Group on Ovarian Cancer, Vniversity Hospital, 3500 CG Vtrech t, Netherlands
LANCET; l/8488 (1028) 1986 The introduction of cisplatin-based combination chemo therapy has improved the results of treatment of advanced ovarian cancer. The percentage of patients achieving a pathologically confirmed complete remission, as determined by a
265
negative second-look laparotomy, is about 30%. Those women with FIG0 stage III or IV who have achieved a complete remission at laparotomy (CRL) survive significantly longer than women in all other response groups: 60-90% of these patients will be continuously free of disease for 5 years. For this reason the percentage of CRL is taken as the ‘gold standard’ by which to assess the efficacy of chemotherapy.
Estrogen replacement therapy in the patient treated for endometrial cancer Creasman WT; Henderson D; Hinshaw W; Clarke-Pearson DL Division of Gynecoiogi? Oncology, Department of Obstetrics and Gynecology, Duke Comprehensive Cancer Center Data Base, Duke University Medical Center, Durham, NC, USA
OBSTET. GYNECOL.;67/3 (326-330) 1986 Adenocarcinoma of the endometrium is considered to be an estrogendependent neoplasia and as such, hormone replacement therapy is said to be contraindicated. The authors are unaware of any data to substantiate that state ment. Patients, who had completed their therapy for stage I carcinoma of the endometrium, were placed on estrogen hormone replacement therapy in a nonrandomized fashion. Between 1975 and 1980, 221 patients with stage I adenocarcinema of the endometrium were managed at the Duke University Medical Center. Forty-seven patients received estrogen after their cancer therapy, whereas 174 patients did not. Risk factors for recurrence were similar between the two groups. After controlling for these known risk factors, the estimated distributions of time to recurrence for the two groups were significantly different (I’< 0.05), with the estrogen group experiencing longer disease-free survival. The history of endometrial cancer does not appear to be a contraindication to hormone replacement therapy in patients with stage I disease.
DISEASES IN PREGNANCY A unique case of abdominal pregnancy: What are the minimal requirements for placental contact with the maternal vascular bed? Noren H ; Lindblom B Department Goetborg,
of
Obstetrics
and Gynecology,
University of
Sahlgren‘s Hospital, S-41 S 45 Goteborg, Sweden
AM. J. OBSTET. GYNECOL.; 155/2 (3944396) 1986 In this report we describe a case of abdominal pregnancy in which the placenta engaged part of the wall of an intraabdominal membranous sac with only minimal vascular connection with the peritoneal surface. A male infant weighing 3150 gm was delivered at 38 weeks’ gestation. We believe this case represents the first report in the literature of an abdominal pregnancy without placental attachment to the maternal viscera. Int J Gynaecol Obstet 25
University NG7 2VH.
UK BR. J. OBSTET. GYNAECOL.; 93/4 (353-360) 1986 Twelve women with stage I endometrial adenocarcinoma were examined by magnetic resonance imaging before definitive surgery. Using this technique the depth of myometrical invasion, tumour site and cervical involvement were assessed and the results compared with the operative and pathological findings. Magnetic resonance imaging is a unique non-invasive method of assessing the early stages of endometrial adenocarcinoma before radiotherapy and surgery.
Random urinary cyclic 3’, 5’ guanosine monophosphate in epithelial ovarian cancer: Relation to other prognostic variables and to survival Luesley DM; Blackledge GR; Chan KK; Newton JR Department Bimingham,
of Obstetrics and Gymsecology. Birmingham, UK
University of
BR. J. OBSTET. GYNAECOL.; 93/4 (380-385) 1986 Random urinary cyclic guanosine monophosphate (cyclic GMP) has been measured in a control group of 83 women and in 92 women with histologically proven epithelial ovarian cancer. Forty-eight cancer patients (53%) had levels greater than the mean +25D of the control population. There was no correlation between urinary cyclic GMP and tumour histology, degree of differentiation or stage. Patients with gross residual disease after laparotomy had higher postoperative levels, This degree of sensitivity in addition to poor specificity for ovarian cancer renders this marker unsuitable for screening purposes. While residual disease state after surgery was found to be the best single predictor of survival, an elevated urinary cyclic GMP level before chemotherapy was found to be an independent adverse prognostic variable.
Complete remission at laparotomy: Still a gold standard in ovarian cancer? Neijt JP; Ten Bokkel Huinink WW; Van Der Burg MEL; Van Oosterom AT Netherlands Joint Study Group on Ovarian Cancer, Vniversity Hospital, 3500 CG Vtrech t, Netherlands
LANCET; l/8488 (1028) 1986 The introduction of cisplatin-based combination chemo therapy has improved the results of treatment of advanced ovarian cancer. The percentage of patients achieving a pathologically confirmed complete remission, as determined by a
265
negative second-look laparotomy, is about 30%. Those women with FIG0 stage III or IV who have achieved a complete remission at laparotomy (CRL) survive significantly longer than women in all other response groups: 60-90% of these patients will be continuously free of disease for 5 years. For this reason the percentage of CRL is taken as the ‘gold standard’ by which to assess the efficacy of chemotherapy.
Estrogen replacement therapy in the patient treated for endometrial cancer Creasman WT; Henderson D; Hinshaw W; Clarke-Pearson DL Division of Gynecoiogi? Oncology, Department of Obstetrics and Gynecology, Duke Comprehensive Cancer Center Data Base, Duke University Medical Center, Durham, NC, USA
OBSTET. GYNECOL.;67/3 (326-330) 1986 Adenocarcinoma of the endometrium is considered to be an estrogendependent neoplasia and as such, hormone replacement therapy is said to be contraindicated. The authors are unaware of any data to substantiate that state ment. Patients, who had completed their therapy for stage I carcinoma of the endometrium, were placed on estrogen hormone replacement therapy in a nonrandomized fashion. Between 1975 and 1980, 221 patients with stage I adenocarcinema of the endometrium were managed at the Duke University Medical Center. Forty-seven patients received estrogen after their cancer therapy, whereas 174 patients did not. Risk factors for recurrence were similar between the two groups. After controlling for these known risk factors, the estimated distributions of time to recurrence for the two groups were significantly different (I’< 0.05), with the estrogen group experiencing longer disease-free survival. The history of endometrial cancer does not appear to be a contraindication to hormone replacement therapy in patients with stage I disease.
DISEASES IN PREGNANCY A unique case of abdominal pregnancy: What are the minimal requirements for placental contact with the maternal vascular bed? Noren H ; Lindblom B Department Goetborg,
of
Obstetrics
and Gynecology,
University of
Sahlgren‘s Hospital, S-41 S 45 Goteborg, Sweden
AM. J. OBSTET. GYNECOL.; 155/2 (3944396) 1986 In this report we describe a case of abdominal pregnancy in which the placenta engaged part of the wall of an intraabdominal membranous sac with only minimal vascular connection with the peritoneal surface. A male infant weighing 3150 gm was delivered at 38 weeks’ gestation. We believe this case represents the first report in the literature of an abdominal pregnancy without placental attachment to the maternal viscera. Int J Gynaecol Obstet 25